26 completed, 10 terminated, 5 active not recruiting, 3 unknown. 48 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 48 | Completed 26, Terminated 10, Active not recruiting 5, Unknown 3, Withdrawn 2, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 2 | Completed 2 |
Follow Stage II Breast Cancer: new trials by email Literature Review of Stage II Breast Cancer trials Research Report on Stage II Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response SHR-A1811 - Early Breast Cancer, HER2 + Breast Cancer | Phase 2 | Not yet recruiting | Chuan Wang | 30 | 2025-10-01 | 2025-08-26 |
| Niraparib + Dostarlimab In BRCA Mutated Breast Cancer Niraparib, Dostarlimab - Stage I Breast Cancer, Stage II Breast Cancer | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 66 | 2021-01-21 | 2026-09-24 |
| Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer Anastrozole, Therapeutic Conventional Surgery, Trastuzumab Deruxtecan - Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 88 | 2020-10-09 | 2025-11-10 |
| MARGetuximab Or Trastuzumab (MARGOT) Paclitaxel, Pertuzumab, Margetuximab - Breast Cancer, Stage II Breast Cancer | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 174 | 2020-07-13 | 2025-11-18 |
| Acupuncture Pilot Study for Cancer-related Cognitive Function Acupuncture, Sham Acupuncture, 16 week waiting period + optional Acupuncture - Stage I Breast Cancer, Stage II Breast Cancer | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 48 | 2019-07-01 | 2026-08-12 |
| Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer Hypofractionated Radiation Therapy - Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma | Phase 2 | Completed | University of Utah | 102 | 2017-12-12 | 2025-12-30 |
| Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery Investigational Imaging device, AVB-620 - Primary Invasive Malignant Neoplasm of Female Breast, Carcinoma Breast | Phase 2 | Completed | Avelas Biosciences, Inc. | 92 | 2017-07-05 | 2021-06-11 |
| Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery Biopsy of Breast - Invasive Breast Carcinoma, Stage II Breast Cancer | Phase 2 | Completed | NRG Oncology | 105 | 2017-04-13 | 2025-05-22 |
| Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca Doxorubicin, Cyclophosphamide, Paclitaxel - Breast Adenocarcinoma, Estrogen Receptor- Negative Breast Cancer | Phase 2 | Active not recruiting | Virginia Commonwealth University | 46 | 2017-01-24 | 2026-07-01 |
| Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer minocycline hydrochloride, placebo, laboratory biomarker analysis - Anxiety Disorder, Depression | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 56 | 2015-06-23 | 2025-01-08 |
| T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA T-DM1, Pertuzumab, Excision of tumor/mastectomy - HER-2 Positive Breast Cancer, Breast Cancer | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 164 | 2015-01-01 | 2026-10-02 |
| Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer fluorouracil, capecitabine, cyclophosphamide - Stage II Breast Cancer, Stage III Breast Cancer | Phase 2 | Unknown | Guangxi Medical University | 100 | 2014-06-01 | 2014-04-15 |
| Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin Simvastatin, Doxorubicin/cyclophosphamide - Breast Cancer, Stage I Breast Cancer | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 34 | 2014-05-20 | 2024-07-09 |
| Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer omega-3 fatty acid, placebo, laboratory biomarker analysis - Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ | Phase 2 | Completed | Wake Forest University Health Sciences | 57 | 2013-11-01 | 2019-10-30 |
| Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer trastuzumab, Pertuzumab, docetaxel - Stage II Breast Cancer, Stage IIIA Breast Cancer | Phase 2 | Completed | Case Comprehensive Cancer Center | 16 | 2013-09-24 | 2019-03-05 |
| Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer telapristone acetate, placebo, therapeutic conventional surgery - Stage IA Breast Cancer, Stage IB Breast Cancer | Phase 2 | Unknown | Northwestern University | 50 | 2013-06-01 | 2020-01-18 |
| Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery Therapeutic Conventional Surgery, Radiation Therapy, Laboratory Biomarker Analysis - Ductal Breast Carcinoma In Situ, Estrogen Receptor Negative | Phase 2 | Terminated | Roswell Park Cancer Institute | 1 | 2013-05-01 | 2017-07-07 |
| Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer Paclitaxel, Carboplatin, Doxorubicin - Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 9 | 2013-04-25 | 2025-04-30 |
| Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 2 | Completed | University of Nebraska | 92 | 2012-12-07 | 2026-06-26 |
| Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer lapatinib ditosylate, paclitaxel, trastuzumab - HER2-positive Breast Cancer, Stage II Breast Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2012-07-01 | 2017-09-11 |
Showing 20 of 48. Sign in to see all of them.
Breast Neoplasms (48) · Breast Neoplasms, Male (8) · Carcinoma, Intraductal, Noninfiltrating (6) · Triple Negative Breast Neoplasms (5) · Breast Carcinoma In Situ (3) · Carcinoma, Ductal, Breast (3) · Inflammatory Breast Neoplasms (3) · Carcinoma, Lobular (2) · Anxiety Disorders (1) · Arthralgia (1) · Colorectal Neoplasms (1) · Depression (1) · Lymphedema (1) · Pain (1) · Prostatic Neoplasms (1)
Breast Diseases (48) · Neoplasms (48) · Neoplasms by Site (48) · Skin Diseases (48) · Skin and Connective Tissue Diseases (48) · Adenocarcinoma (7) · Carcinoma (7) · Neoplasms by Histologic Type (7) · Neoplasms, Ductal, Lobular, and Medullary (7) · Neoplasms, Glandular and Epithelial (7) · Carcinoma in Situ (6) · Breast Carcinoma In Situ (3) · Carcinoma, Ductal (3) · Behavior (1) · Behavioral Symptoms (1)
Cyclophosphamide (15) · Doxorubicin (14) · Paclitaxel (14) · Taxes (11) · Trastuzumab (8) · Carboplatin (5) · Filgrastim (5) · Granulocyte Colony-Stimulating Factor (5) · Anastrozole (4) · Bevacizumab (4) · Capecitabine (4) · Letrozole (4) · Radiation (4) · Radiotherapy (4) · Tamoxifen (4)
University of Washington (6) · Dana-Farber Cancer Institute (5) · National Cancer Institute (NCI) (5) · Case Comprehensive Cancer Center (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Northwestern University (2) · University of Nebraska (2) · Avelas Biosciences, Inc. (1) · Chuan Wang (1) · Clinica Universidad de Navarra, Universidad de Navarra (1) · Guangxi Medical University (1) · Harold J. Burstein, MD, PhD (1) · Jonsson Comprehensive Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · NRG Oncology (1)
United States (45) · Canada (1) · China (1) · Japan (1) · Spain (1)
Adrienne Waks, MD (2) · Hannah Linden (2) · Vered Stearns (2) · Amulya C Yellala, MD (1) · Anthony Elias, M.D (1) · Bhuvaneswari Ramaswamy, MD (1) · Bruce Haffty, MD (1) · Charles Kunos, MD (1) · David Mattson (1) · Dawn Hershman (1) · Dennis Holmes (1) · Edith Mitchell, MD (1) · Edward Levine, MD (1) · Elizabeth C Reed, MD (1) · Eric Winer, MD (1)
PMID 24068539, PMID 24464780, PMID 26006067, PMID 33740205, PMID 34987618, PMID 38300710, PMID 40314623, PMID 40332918
N01CM62204 (2), P30CA036727 (2), N01CM62202 (1), P30CA006973 (1), P30CA012197 (1), P30CA013330 (1), P30CA015704 (1), P30CA016056 (1), P30CA016059 (1), P30CA023074 (1), P30CA043703 (1), P30CA072720 (1), R01CA127927 (1), U01CA070095 (1), U10CA021115 (1)